JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE
NMPA APPROVAL OF RELMA-CEL IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

JW (Cayman) Therapeutics Co. Ltd (the "**Company**" or "**JW Therapeutics**", together with its subsidiaries, the "**Group**"), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce that the National Medical Products Administration of China (the "**NMPA**") has approved the supplemental New Drug Application for its anti-CD19 autologous chimeric antigen receptor T ("**CAR-T**") cell immunotherapy product relmacabtagene autoleucel injection ("**relma-cel**", trade name: Carteyva®) for the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment ("**r/r FL**"). This is the second approved indication for relma-cel following its initial approval and launch in September last year, and makes it the first cell immunotherapy product approved in China for the treatment of r/r FL patients.

This approval is based on the 6-months clinical results from cohort B of a single-arm, multi-center, pivotal study (the "**RELIANCE study**") on Carteyva® in adult patients with r/r B cell non-Hodgkin lymphoma in China. The 3-months data were presented at the 63rd American Society of Hematology Annual Meeting in December 2021. The cohort B results of the RELIANCE study showed that Carteyva® demonstrated very high rates of durable disease response (overall response rate ("**ORR**")=100%, complete response rate ("**CRR**")=85.19% at month 3; ORR=92.58%, CRR=77.78% at month 6) and controllable CAR-T associated toxicities in patients with r/r FL. Given the currently available treatments in China, Carteyva® may become a treatment option with a higher benefit-risk ratio for patients with r/r FL, and has the potential to become a best-in-class CAR-T product.

Professor Yuqin Song, the principal investigator of the RELIANCE study, Deputy Director of Lymphoma Department, Vice President of Peking University Cancer Hospital, commented, "the overall response rate of the efficacy endpoint was over 90%, and the overall safety profile was manageable. Relma-cel has become the first CAR-T cell immunotherapy product for the treatment of the r/r FL in China."

Dr. Yiping James Li, co-founder, Chairman and Chief Executive Officer of JW Therapeutics, said, "Thanks to the patients and investigators who contributed to the clinical studies of Carteyva®, and thanks to the regulators for the recognition of Carteyva®. We are pleased with the second approved indication, which provides a new and breakthrough treatment option for r/r FL patients. JW Therapeutics is committed to maximizing the value of Carteyva®, continuously advancing technology innovation and pipeline development, and improving the accessibility of cell immunotherapy products."

As the first product of JW Therapeutics and the first CAR-T product approved as a Category 1 biologics product in China, relma-cel has been approved for two indications in China, including for the treatment of adult patients with r/r large B-cell lymphoma ("**LBCL**") after two or more lines of systemic therapy, and for the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment ("**r/r FL**"). Currently, to fully explore the clinical potential of Carteyva®, JW Therapeutics is conducting or planning to conduct more clinical studies on hematologic malignancies and autoimmune diseases, including third-line mantle cell lymphoma, third-line acute lymphoblastic leukemia, frontline and second-line LBCL, and systemic lupus erythematosus.

About relma-cel (trade name: Carteyva®)

Relma-cel (trade name: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics, Inc. (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, relma-cel (Carteyva®) has been approved by the NMPA for two indications, including the treatment of adult patients with r/r LBCL after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment ("**r/r FL**"), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations.

About JW Therapeutics

JW Therapeutics (Stock Code: 2126) is an independent and innovative biotechnology company focusing on the developing, manufacturing and commercializing cell immunotherapy products. Founded in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The Company has built a top world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring hope of cure for Chinese and global patients, and to lead the healthy and standardized development of China's cell immunotherapy industry.

For more information, please visit **www.jwtherapeutics.com**.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: JW Therapeutics cannot guarantee that it will be able to develop, or ultimately market relma-cel successfully. Shareholders and potential investors of JW Therapeutics are advised to exercise due care when dealing in the shares of JW Therapeutics.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Yiping James Li
Chairman

Shanghai, PRC, October 10, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yiping James Li as Chairman and executive Director, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Chi Shing Li, Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.

* *For identification purpose only*